Although achieved within a small cohort, these results align with the proposed clinical efficacy of HDC/IL-2 in younger AML patients carrying NPM1 mutations, including those with AML of myelomonocytic/monocytic morphology (FAB-M4/M5 AML).42 This evidence concerns the gene NPM1 and acute myeloid leukemia.